ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Plans Drug Plant In U.K.

by Alex Scott
November 25, 2013 | APPEARED IN VOLUME 91, ISSUE 47

AstraZeneca says it will invest $190 million to build a new production plant in Macclesfield, En­gland, to make its Zoladex injectable drug for treating prostate cancer. The plant is due to open in 2017. The investment secures the jobs of 300 staff at the existing Zoladex facilities in Macclesfield, AstraZeneca says. The firm selected Macclesfield so that it can draw on local expertise gathered from more than two decades of Zoladex production in the town. Zoladex is currently the firm’s fifth-largest-selling drug, with annual sales of about $1 billion.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment